Scalable from lab scale up to a maximum of 4 L! Designed to maximize product recovery rate.
The "LV Centramate" is a product designed for the scale-up and scale-down of tangential flow filtration process development, small batch production of biopharmaceutical processes, scale-down testing, and the production of materials for safety and efficiency studies (Phase I clinical trials). With a low residual volume, it achieves high concentration factors from a small starting volume. Since it has the same flow path length as the Centramate cassette holder and Centrasette cassette holder, linear scale-up is possible. In a 2010 study, LV Centramate was used for the concentration of AAV viruses purified from cell culture supernatant [1]. 【Features】 ■ Linear scale-up is possible ■ Can also be used in conjunction with other lab TFF systems ■ Achieves high concentration factors from a small starting volume due to low residual volume ■ Easy connection with SUS316L polished luer lock ports, ensuring the same compatibility characteristics as the production scale Centrasette holder [1] Vandenberghe, et al., Human Gene Therapy. 21. 1251-1257 (2010).
Inquire About This Product
basic information
【Other Features】 ■ Designed for scale-up and scale-down of tangential flow filtration (TFF) process development, small batch production of biopharmaceutical processes, scale-down testing, and production of materials for safety studies and efficiency studies (Phase I clinical). ■ Has the same flow path length as Centramate cassette holders and Centrasette cassette holders. ■ The LV Centramate holder can also be used in conjunction with other lab TFF systems to enhance scalability characteristics. ■ Scalable to production scale and optimized for processing typical usage amounts during development and new drug discovery phases. *For more details, please refer to the PDF materials or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Applications】 ■ Concentration of biomolecules ■ Recovery and purification of biomolecules from cell culture supernatants and lysates ■ Diafiltration, desalting, and buffer exchange of biomolecules ■ Fractionation of mixed molecular solutions *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
